drugset / Trial / NCT01755416
Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting
RandomizedCrossoverOpen-labelTreatment
Summary
Hypothesis: In type 1 diabetes mellitus, in the setting of a closed loop glucose control system: adjunctive therapy with Liraglutide will afford better post-prandial glycemic excursions than insulin mono-therapy. Specific Aim: To determine if post-prandial glucose excursions are lowered with the addition of Liraglutide compared to insulin mono-therapy. Study Design: This is a randomized open labeled crossover design trial comparing adjuvant Liraglutide and insulin Vs. insulin mono-therapy using the ePID closed-loop system for insulin delivery.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Liraglutide | Peptide | 1.2 mg | Subcutaneous |
| Comparator | Insulin | Protein / enzyme biologic | — | — |